My Salon Suite

MARCH 10, 2025

At MY SALON Suite Oakland , California, Vee Vargas is not only creating stunning hair but also inspiring an entire industry with her visionary work. As the owner of Be Here Salon at MY SALON Suite , she is at the forefront of innovation and empowerment, shaping a future where beauty spaces are inclusive and nurturing for all. A Visionary Recognized Vee Vargas’s innovative approach and dedication have earned her a finalist spot for the prestigious NAHA Award for Inspiring Salon of the Year

Salon 76

Salon Innovations Sustainability Education 76

Lori Crete

MARCH 10, 2025

Welcome back to The Beauty Biz Show! In this episode, double board-certified dermatologist and experienced inventor Dr. Steven Hacker joins Lori to discuss his entrepreneurial journey, the role of estheticians in dermatology, and all things dermaplaning. Tune in to learn more about Dr. Hacker’s latest invention, the Lumohs Dermaplane, and how it can transform your esthetics practice.

Dermaplaning 61

Dermaplaning Entrepreneurship Social Media Esthetician 61

Salon Today

MARCH 10, 2025

In Day 10 of revealing our 2025 SALON TODAY 200, we visit the second half of the Growth honorees, including the team from Studio Wish in Twinsburg, Ohio.

Salon 105

Salon 105

West Lake Dermatology

MARCH 10, 2025

Mohs surgery is a specialized, highly effective technique for the removal of skin cancer. Among treatment options, Mohs surgery uniformly produces the highest success rate and has the lower risk of tumor recurrence. However, for many prospective patients the idea of undergoing Mohs surgery can feel intimidating. It is natural to have concerns about what the procedure entails and how the day will unfold.

Surgery 36

Surgery Scarring Injections Clinic 36

The Dermatology Digest

MARCH 10, 2025

Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. Th e Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

Dermatology Times

MARCH 10, 2025

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients.

78

78

Dermatology Times

MARCH 10, 2025

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Technology 72

Technology Microneedling Clinic 72

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treat

Dermatitis 36

Dermatitis Safety Office Eczema 36

Dermatology Times

MARCH 10, 2025

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Therapy 65

Therapy Scarring Treatments 65

The Dermatology Digest

MARCH 10, 2025

More than 63% of hidradenitis suppurativa (HS) patients who took bimekizumab (Bimzelx, UCB) for two years had no or mild skin pain, a substantial improvement from 10% at baseline. Of 425 HS patients with one or more draining tunnel (DT) at baseline, 55.7% had no DTs at two years of treatment. Christopher Sayed, MD, a Dermatologist at the University of North Carolina Chapel Hills HS Clinic in Durham, NC, discusses the results of the study, which were presented at the American Academy of Dermatolo

Dermatology 36

Dermatology Clinic Treatments 36

Dermatology Times

MARCH 10, 2025

Brian S. Kim, MD, FAAD, shares itch research updates at the AAD Annual Meeting.

Management 61

Management Therapy 61

Dermatology Times

MARCH 10, 2025

The recall includes L'Oral's Effaclar Duo product. Stay tuned for more updates throughout the day.

60

60

Dermatology Times

MARCH 10, 2025

Stark highlighted Bimzelxs role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Innovations 54

Innovations 54

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

Dermatology Times

MARCH 10, 2025

Medicus previous phase 1 study confirmed D-MNAs safety, with some participants achieving complete BCC clearance.

Safety 53

Safety Treatments 53

Dermatology Times

MARCH 10, 2025

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Dermatology 41

Dermatology 41

Dermatology Times

MARCH 10, 2025

According to a poster from AAD, the National Psoriasis Foundations treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Treatments 41

Treatments 41

Dermatology Times

MARCH 10, 2025

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Dermatology 36

Dermatology 36

Dermatology Times

MARCH 10, 2025

Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.

Dermatitis 36

Dermatitis Management Treatments 36